Journal
AUTOIMMUNITY REVIEWS
Volume 12, Issue 12, Pages 1115-1117Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2013.06.011
Keywords
Abatacept; Rheumatoid arthritis; Safety
Categories
Ask authors/readers for more resources
Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor, and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available